Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 25;7:14049. doi: 10.1038/s41598-017-14417-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Combination therapy with anti-PD-1 and anti-CD4 mAb significantly prolong NXS2-tumor-free progression in mice. (a) Kaplan-Meier analysis of A/J mice challenged i.v. with a tumorigenic dose of NXS2-luc cells on day 0 and then treated with anti-PD-1 and anti-CD4 mAb shows a significant increase in mice survival, with 2/6 mice cured from disseminated tumors. P values of combined treatments vs irrelevant Ab controls are indicated (Wilcoxon log-rank test). The experiment shown is representative of two independent ones with identical results. (b) The combined treatment with anti-PD-1 and anti-CD4 mAb potently inhibits Neuroblastoma progression even if started at a later time point (+6 days from challenge). P values of delayed combined treatments vs irrelevant Ab controls are indicated (Wilcoxon log-rank test). Percentages of progression-free mice are indicated on the Y-axis and the fraction of progression-free mice of each group is given in brackets.